Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

3(42.9%)

Phase 4

1(14.3%)

Phase 2

1(14.3%)

Phase 1

1(14.3%)

N/A

1(14.3%)

7Total

Phase 3(3)

Phase 4(1)

Phase 2(1)

Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01554813Phase 3Completed

Clinical Trial of Inactivated Influenza Vaccine (0.5ml Formulation)

Role: lead

NCT01554826Phase 3Completed

Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use)

Role: lead

NCT01511744Phase 4Completed

Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine

Role: lead

NCT01661738Phase 2Completed

Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 002

Role: lead

NCT01661725Phase 1Completed

Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 001

Role: lead

NCT01661751Phase 3Completed

Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 003

Role: lead

NCT01568788Not ApplicableCompleted

Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine

Role: lead

All 7 trials loaded